|1.||Bartoszyk, Gerd D: 4 articles (12/2011 - 03/2006)|
|2.||Russ, Hermann: 3 articles (04/2008 - 03/2004)|
|3.||Goetz, Christopher G: 3 articles (04/2008 - 03/2004)|
|4.||Rascol, Olivier: 3 articles (04/2008 - 03/2004)|
|5.||Damier, Philippe: 3 articles (04/2008 - 03/2004)|
|6.||Bartoszyk, G D: 2 articles (06/2009 - 02/2004)|
|7.||Hicking, Christine: 2 articles (04/2008 - 01/2007)|
|8.||Laska, Eugene: 2 articles (04/2008 - 01/2007)|
|9.||Müller, Thomas: 2 articles (04/2008 - 01/2007)|
|10.||Nutt, John: 2 articles (04/2008 - 03/2004)|
04/15/2008 - "Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. "
01/01/2012 - "This reaction, which has been successfully applied to the formal synthesis of the anti-dyskinesia agent sarizotan, further extends the use of ynamides in organic synthesis and further demonstrates the synthetic efficiency of carbometallation reactions."
07/01/2009 - "The time course of plasma sarizotan concentrations was associated with time of maximal reduction of dyskinesias. "
04/15/2008 - "Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. "
01/15/2007 - "Sarizotan 2 mg/day is a safe agent in PD patients with dyskinesia. "
|2.||Parkinson Disease (Parkinson's Disease)
01/15/2007 - "The objective of this study is to conduct a dose-finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. "
01/15/2007 - "Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial."
04/01/2006 - "The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. "
03/01/2004 - "Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)."
06/01/2009 - "These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson's disease."
|3.||Parkinsonian Disorders (Parkinsonism)
12/01/2011 - "These data suggest that sarizotan may have some antidepressant-like and restorative properties in Parkinsonism."
12/01/2011 - "Antidepressant-like properties of sarizotan in experimental Parkinsonism."
04/15/2008 - "Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. "
06/01/2009 - "Since 5-HT(1A) receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT(1A) agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism. "
|4.||Movement Disorders (Movement Disorder)
03/01/2006 - "Because 5-HT1A agonists are known to counteract antipsychotic-induced motor side effects, sarizotan was investigated for its effects in two rat models of tardive dyskinesia (TD). "
03/01/2006 - "The acute administration of sarizotan (0.17-13.5 mg/kg i.p.) reduced episodes of SKF 38393-induced repetitive jaw movements (RJM) in rats with a maximal effect at 1.5 mg/kg. In a chronic study, sarizotan (0.04-9 mg/kg/day), administered in the drinking water for 7 weeks during withdrawal from chronic haloperidol treatment (1.5 mg/kg/day), dose-dependently reversed haloperidol-induced RJM, significant at the doses of 1.5 and 9 mg/kg. Agonism at 5-HT1A receptors may be mediating the inhibitory effect of sarizotan on RJM in rat models of tardive dyskinesia."
03/01/2006 - "The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia."
09/01/2006 - "Sarizotan effectively suppresses levodopa-induced dyskinesia in primate and rodent models of Parkinson's disease, and tardive dyskinesia in a rodent model. "
09/01/2006 - "When 5-HT1A receptors were blocked by pretreatment with WAY100635 (2.5 mg/kg, s.c.), cataleptogenic properties of SSR181507 and sarizotan were unmasked, and the catalepsy induced by bifeprunox was enhanced. "
08/01/2005 - "However, when 5-HT(1A) receptors were blocked with the selective antagonist, WAY100635 (0.63 mg/kg, SC), robust cataleptogenic properties of SLV313, bifeprunox and sarizotan were unmasked and the catalepsy induced by ziprasidone was accentuated. "
08/01/2005 - "Whereas ziprasidone and aripiprazole did not markedly reduce the effects of haloperidol, SLV313 and sarizotan attenuated CLP catalepsy. "
08/01/2005 - "When administered alone, ziprasidone produced marked catalepsy, whereas aripiprazole, bifeprunox, SLV313, SSR181507 and sarizotan did not. "
09/01/2006 - "In the bar catalepsy test, when administered alone, haloperidol, olanzapine and risperidone produced marked catalepsy, whereas, at doses up to 40 mg/kg, aripiprazole, SLV313, SSR181507, and sarizotan produced little or no catalepsy. "
|1.||Levodopa (L Dopa)
|4.||Serotonin 5-HT1 Receptor Agonists
|5.||Oxidopamine (6 Hydroxydopamine)
|6.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|7.||Serotonin (5 Hydroxytryptamine)
|9.||1- (2,3- dihydro- 1,4- benzodioxin- 5- yl)- 4- ((5- (4- fluorophenyl)- 3- pyridinyl)methyl)piperazine
|10.||(3- exo)- 8- benzoyl- N- (((2S)7- chloro- 2,3- dihydro- 1,4- benzodioxin- 1- yl)methyl)- 8- azabicyclo(3.2.1)octane- 3- methanamine monohydrochloride